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OBSERVATIONS ON THE ABSORPTION, EXCRETION,
DIFFUSION, AND ACETYLATION OF
SULFATHIAZOLE IN MAN*
JOSEPH F. SADUSK JR., FRANCIS G. BLAKE, AND ANNE SEYMOUR
The sulfonamide derivatives differ from compound to compound
not only in scope and effectiveness of chemotherapeutic action4 but
also in their pharmacological properties."8 It becomes important,
therefore, with each new compound introduced, after preliminary
studies in animals, to determine the facts concerning these proper-
ties in man. In this paper are recorded observations in man on the
absorption, excretion, diffusion into body fluids, and acetylation of
sulfathiazole,t recently introduced by Fosbinder and Walter8 and
Lott and Bergeim,17 and already shown12'6' 14,21 to be chemothera-
peutically active in a variety of experimental infections in mice as
well as bacteriostatic in vitro.11' 13 14 The studies were made in part
on individuals not receiving chemotherapeutic treatment, in part on
patients with acute infections, mostly pneumococcal pneumonia,
undergoing therapy with sulfathiazole.
Previous studies on the pharmacological properties of sulfathia-
zole in experimental animals by van Dyke, Greep, Rake, and
McKee7 indicate that sulfathiazole is more rapidly metabolized and
is much less acetylated than is sulfapyridine. The latter observa-
tion is supported by experiments in mice reported by Barlow and
Homburger.2 Long, Haviland, and Edwards15 likewise have found
that sulfathiazole is absorbed more readily and excreted more
rapidly in mice than is sulfapyridine and have noted that in man, in
comparison with sulfapyridine, definitely less of the sulfathiazole
excreted in the urine is in the conjugated form.
Reinhold, Flippin, and Schwartz,23 in a study of the pharma-
cological properties of sulfathiazole in man, found that it was rapidly
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absorbed from the gastro-intestinal tract, commonly attaining its
peak of concentration in the blood less than 4 hours after a single
oral dose. Recovery of the ingested sulfathiazole in the urine varied
from about 60 per cent to 93 per cent in 24 hours and was practically
quantitative following intravenous administration of the sodium salt.
The proportion of the drug conjugated was low in most instances.
Materials and methods
Observations on the rate of absorption of sulfathiazole from the gastro-
intestinal tract, as measured by frequent determinations of blood concentration
following a single dose of 0.06 gm./K per os, were made in one normal
adult male and compared with the data obtained following similar single oral
and intravenous doses, respectively, of sodium sulfathiazole in another indi-
vidual. In addition, in order to establish the range of individual variation, the
blood concentration attained 4 hours after a single initial oral dose of 4.0 gm.
of sulfathiazole was determined in 32 patients.
Ten studies on the excretion of sulfathiazole in the urine, either following
a single dose of 0.06 gm./K or an initial dose of 4.0 gm. per os followed by
1.0 gm. every 4 hours, were conducted in 9 individuals over varying periods
of time.
The rate and degree of diffusion of sulfathiazole into body-fluids, as com-
pared with simultaneously determined blood concentrations, were studied in
14 instances, either after a single dose of 4.0 gm. of sulfathiazole given orally
or an initial dose of 4.0 gm. followed by 1.0 gm. every 4 hours. Four of
these observations were on pleural effusions, 4 were on ascitic fluids from
cases of hepatic cirrhosis, and 6 were on non-inflammatory spinal fluids from
patients receiving diagnostic lumbar puncture. A few similar studies with
sulfamethylthiazole are included.
In order to determine the range of variation in blood concentration that
may occur in patients under continued treatment with sulfathiazole, daily
blood determinations were made just prior to the 8:00 A. M. dose in a series
of patients most of whom had pneumococcal pneumonia. The results in 82
courses of therapy in 79 cases, in whom the treatment consisted of an initial
dose per os of 4.0 gm. followed by 1.0 gm. q. 4 h. for 5 to 8 days, are
presented.
In all the foregoing observations the concentration of both free and total
sulfathiazole was determined, thus providing a mass of material on the degree
of acetylation of sulfathiazole which occurs in man.
The method of Marshall and Litchfield20 was used in determining the
concentration of sulfathiazole in blood, urine, and body fluids. Readings
were made with a photoelectric colorimeter, a 1:50 dilution of blood and
body fluids and appropriate dilutions of urine being used. Observations on
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blood with added sulfathiazole indicate a possible minus error of 7 to 16 per
cent. Determinations on urine are approximately accurate. In the collection
of pleural and spinal fluids ethyl chloride was used as a local anesthetic in
order to avoid error from the presence of novocaine.16 Adequate precautions
were also observed in the collection of ascitic fluids.
Observations
Absorption of sulfathiazole
The rate of absorption of sulfathiazole in a normal adult male
following a single oral dose of 4.2 gm. (0.06 gm./K body weight),
as measured by blood concentration, is shown in Fig. 1. It will be
noted that the peak of concentration occurred 3 hours after ingestion
and that the
blood level had q ONE SNGLE DOSE-0.06 GM./KGM. BODY WGHT.
already fallen 8 - SODFAHIAZa MX.
considerably by S7
6 hours. This in- 6 ' dicates ready ab- ,5
sorption, fairly 4
-
comparable in 93.
rate to that of a'1'
sulfanilamide.t
Since the curve 9 t34 86^2E X6 Sincethe curve ~~~~~ 6 H AFTER DOSE OF DRUG
represents acom- FIG. 1. Concentrations of total and free sulfathiazole posite of absorp- in the blood following a single dose of sodium sulfathiazole tion, diffusion, intravenously, sodium sulfathiazole orally, and sulfathiazole
and excretion, it orally.
should be re-
corded that 1.68 gm., or 40 per cent, of the ingested dose was
excreted in the urine during the first 6-hour period.
For comparison the curves of blood concentration following
similar single intravenous and oral doses, respectively, of sodium
sulfathiazole, were determined in a patient with subacute bacterial
endocarditis, and are included in Fig. 1. It will be noted that the
highly soluble sodium salt was absorbed very rapidly from the
gastro-intestinal tract, the curve being almost the same as that
obtained following intravenous injection. In the first 6-hour period
approximately 40 per cent and 36 per cent, respectively, of the
administered drug were recovered in the urine.
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Judging from previous experience with sulfapyridine,5 absorp-
tion of sulfathiazole from the gastro-intestinal tract may be expected
to vary considerably from individual to individual, particularly in
the presence of disease. The results of observations on blood con-
centration 4 hours after a single initial dose of 4.0 gm. of sulfathia-
zole in 32 cases, of whom 17 had pneumococcal pneumonia, 4 had
other infections, and 11 had miscellaneous conditions not under
treatment, are shown in Table 1. The concentrations found ranged
from 1.4 to 8.1 mgm. per cent, the majority falling between 3.0
and 5.9 mgm. per cent. These figures obviously indicate a consider-
TABLE 1
VARIATIONS IN CONCENTRATION OF SULFATHIAZOLE IN THE BLOOD 4 HOURS AFTER A
SINGLE ORAL DOSE OF 4.0 GM. OF SULFATHIAZOLE IN 32 CASES
Total sulfathiasok No. of cases
1.0- 1.9mgm. % 2
2.0-2.9 mgm. % 5
3.0- 3.9 mgm. % 7
4.0-4.9 mgm.ni.% 4
5.0-5.9mgm. % 9
6.0 -6.9 mgm. % 3
7.0-7.9 mgm.% 1
8.0-8.9 mgm. % 1
1.4- 8.1 mgm. % 32
able individual variation in the rate of absorption of sulfathiazole and
are comparable to similar variations found with sulfapyridine.
Excretion of sulfathiazole
Observations on the excretion of sulfathiazole in the urine in a
normal adult male during a 24-hour period following a single oral
dose of 4.2 gm. (0.06 gm./K body weight) are shown in Table 2.
For comparison the data of similar studies following single intra-
venous and oral doses, respectively, of sodium sulfathiazole given a
patient with subacute bacterial endocarditis are also shown. It will
be seen that the results are quite similar in all three experiments,
approximately 40 per cent of the administered sulfathiazole having
been excreted in the first 6 hours and 70 to 80 per cent by the end of
24 hours, at which time only traces remained in the blood.
In order to obtain information concerning variations in the
amount of sulfathiazole excreted in the urine in cases under con-
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tinued treatment, similar observations were made in 7 patients over
periods of time ranging from 2 to 9 days. The summarized data
TABLE 2
EXCRETION OF SULFATHIAZOLE IN THE URINE FOLLOWING A SINGLE DOSE OF 0.06 GM./K
BODY WEIGHT
Hour-s Blood Urine
Subject after admin. Sulfathiazole Vol- Sulfathiazole excreted
Q a a Free Total Acet. ume Free Total Acet. Recovered
gm. mngm. mgm. gm. gm. % %
% % % cc.
J. S. ST * Oral 4.2 0 3.4 3.4 -
'/2 3.4 3.4 -
1 5.0 5.3 6
Normal l/2 6.1 6.4 5
3 8.2 8.8 7
6 5.0. 6.1 18 660 1.48 1.68 12 40.0
12 1.8 2.9 38 412 0.73 0.91 20 21.7 61.7
18 0.8 1.3 39 260 0.25 0.35 29 8.3 70.0
24 0.5 0.6 17 325 0.15 0.20 25 4.8 74.8
T. G. NaST i.v. 2.8 01/2 8.0 8.5 6
Subacute IY2 6.2 6.5 5
3 4.6 4.9 6
bacterial
endocarditis 6 395 1.09 1.19 8 42.5 ...
12 0.9 1.7 47 285 0.52 0.67 22 23.9 66.4
18 TR. TR. 130 0.19 0.28 32 10.0 76.4
24 TR. TR. ... 125 0.04 0.07 43 2.5 78.9
T. G. NaST oral 2.8 0
4 7.2 7.3 1
Subacute 1 4 6.7 6.9 3
3'/2 4.6 5.1 10
bacterial 6 3.4 4.0 15 225 0.96 1.02 6 36.4 ...
12 1.9 2.0 5 150 0.36 0.46 22 16.4 52.8
endocarditis 18 0.9 0.9 - 160 0.29 0.38 24 13.6 66.4
24 0.5 0.7 ... 335 0.10 0.13 23 4.6 71.0
*ST= sulfathiazole. NaST = sodium sulfathiazole. i.v. = intravenous. TR. =
<0.5 mgm. %.
are shown in Table 3, from which it will be seen that the amount of
administered drug recovered in the urine varied considerably from
patient to patient. While differences in renal function might obvi-
ously be a factor influencing the output of sulfathiazole in the urine,
it would seem more probable in this group of cases, at least, that
variations in the amount of drug absorbed were of more significance,
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inasmuch as themaxitium concentration attained in the blood was in
no case higher than usual with the dosage employed.
Diffusion into body fluids
Data concerning the rate and degree of diffusion of sulfathiazole
into pleural and ascitic fluids are shown in Table 4. In seven obser-
vations 4 hours after an oral dose of 4.0 gm. of sulfathiazole the
TABLE 3
EXCRETION OF SULFATHIAZOLE IN THE URINE IN PATIENTS RECEIVING AN INITIAL DOSE OF
4.0 GM. FOLLOWED BY 1.0 GM. Q.4 H.
Sulfa thiaso le
Administered Blood Recovered in urine
Case Clinical Total Daysof Maxi- Daysof % of Acetylated
diagnosis dose adminis- mum conc. excre- total dasly
gm. tration mgm. 9% tion dose %
F. T.
A.B. Encephalitis (post) 10 1 6.8 7.5 2 63.4 10
R.Ch. Arterioscl.ht. dis. 10 1 6.6 7.4 2 53.1 14
R.C. Cirrhosis ofliver* 10 1 5.9 6.0 2 27.9 14
H.P. Meningococcemia 38 6 4.8 5.1 8 81.8 8-16
P.C. Lobarpneumonia 37 5X2 3.9 4.2 7 61.0 6-20
J.M. Lobarpneumonia 27 4 4.8 5.4 6 44.6 12-32
E.A. Lobarpneumonia 40 6 4.6 5.5 9 57.4 8-20
* With ascites and edema.
concentration of total sulfathiazole in the fluids varied between 18.6
and 86.7 percent of the blood concentration. At this time, however,
only free sulfathiazole had entered the fluids. At 24 hours after
the initial dose the total sulfathiazole concentration in the fluids
had increased to 82.9 per cent as the minimum to 147.4 per cent of
that in the blood. Conjugated sulfathiazole was now present in
amounts ranging from 3.5 to 24.6 per cent of the total. A single
experiment with sulfamethylthiazole gave similar results. These
observations indicate that sulfathiazole diffuses readily and at a
fairly rapid, though somewhat variable, rate into pleural and ascitic
fluids, with some lag in outward diffusion as blood concentration
falls. These results aresimilarto those occurringwith sulfapyridine.
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Information concerning diffusion of sulfonamide compounds
into spinal fluid is of importance in relation to the treatment of
meningitis. Studies of this problem were conducted with sulfathia-
zole in 6 patients and with sulfamethylthiazole in 2 patients, none
TABLE 4
DIFFUSION OF SULFATHIAZOLE INTO PLEURAL AND ASCITIC FLUIDS
Sulfathiazole
Blood Body Fluid
Case Body Hours Per cent Remars
fluid Dosage, gin. after of Blood
Reak
initiall - CO.
Initial Subsequent dose Free Total Free Total (total)
mgm. % mgm. %
R.Ch. Pleural 4.0 1.0 q.4 h. (6x) 4 5.8 6.0 5.1 5.2 86.7 Hydrothorax,
24 6.8 7.1 8.1 9.6 135.2 cardiac
.____ .____________ ____________ 48 1.2 1.4 4.8 5.3 378.6 failure
C.R. Pleural 4.0 1.0 q.4 h. (5x) 4 2.0 2.0 1.0 1.0 50.0 HydrothoraX,
24 1.7 1.9 2.7 2.8 147.4 cardiac
l_______ _____ ______________ _____ __________ _ ________ ________ failure
K*M. Pleural 4.0 1.0 q.4 h. (5x) 4 5.0 5.5 3.1 3.1 56.4 Tuberculous
24 3.7 4.1 4.8 5.3 129.3 effusion
S.A. Pleural 4.0 1.0 q.4 h. (5x) 4 7.1 8.1 2.4 2.4 29.6- Tuberculous
24 4.9 6.1 5.6 6.1 100.0 effusion
R.C. Ascitic 4.0 4 2.7 3.3 0.8 0.8 24.2 Hypertensive, as .. 4.0 1.0 q.4 h. (6x) 24 4.8 6.0 4.9 .6.5 108.3 cirrhosis of " Pleural I . . 86 ie cric Ascitic }| 4.0* 1.0*q.4 h. (5x) 24 3.4 5.1 1f3. 3.5 68. liver(card IC)
C.M. Ascitic 4.0 4 5.4 5.9 1.0 1.1 18.6 Cirrhosis of
|_______ _____ I_____________ liver
M.T. Ascitic 4.0 4.0 at 6 and 4 3.0 3.1 0.8 0.8 25.8 Cirrhosis of
10 hrs. 24 6.1 7.6 5.5 6.3 82.9 liver
* Sulfamethylthiazole.
of whom had evidence of acute inflammation of the meninges. *No
opportunity to make observations in cases of acute meningitis has as
yetpresented itself. The results are shown in Table 5. In 6 observa-
tions made at 4 hours after an initial oral dose of 4.0 gm.n of thiazole
compound, it was found that none or only slight traces of the drug
had entered thespinal fluid. Even after 18 to 43 hours of continued
treatment relatively little sulfathiazole had passed into the spinal
fluid, the maximum amount being only 25.9 per cent of that in the
blood at the same time. Little or no conjugated sulfathiazole was
present.
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The failure of sulfathiazole to diffuse readily into the spinal
fluid is in marked contrast with the diffusibility of sulfanilamide and
sulfapyridine. A comparison of sulfathiazole and sulfapyridine is
shown in Fig. 2. Whether sulfathiazole will enter the spinal fluid
TAB= 5
DIFFUSION OF SULFATHIAZOLE AND INTO SPINAL FLUID
Dosage, gm.
Subsequent
. q4. (5
1.0q.4h. (5x)
1.0q.4h. (Ox)
1.0q.4h. (6x)
1.0q.4h. (6x)
after
initial
dose
4
4
4
24
4
24
18
43
24
4
4
Sulfa thiazo le
Blood
Free Total
mgm. %
4.1 4.2
4.6 5.3
6.1 6.4
4.4 4.9
2.4 2.4
5.3 5.9
4.8 5.9
4.2 5.8
5.0 5.4
4.6 4.7
8.3 8.7
Spinal fluid
Free Total
mgm. %
TR.
0.0
TR.
0.9
0.0
0.6
0.7
0.5
1.3
TR.
0.0
TR.
0.9
0.0
0.9
0.8
0.5
1.4
TR. TR.
TR. TR.
Per cent
of blood
COC.
(total)
* ......
0.0
* ......
18.4
0.0
15.3
- 13.6
8.6
25.9
Central
nervous
system
Normal
Syphilis
Normal
Normal
Normal
Post-
encephalitic
Parkinsonism
Syphilis
...... .ISyphilis
*ST
= sulfathiazole; SMT
= sulfamethylthiazole. TR. = < 0.5 mgm. %0.
in larger amount in the presence of acute inflammatory meningitis
remains to be determined.
Variations in blood concentration under continued treatment uith
sulfathiazole.
It has already been pointed out that there is considerable indi-
vidual variation in absorption of sulfathiazole from the gastro-intes-
tinal tract, a fact which might be expected to result in variations in
blood concentration from patient to patient under continued treat-
Case
G.L.
A.V.
P.R.
H.R.
M.S.
A.B.
R.B.
I.H.
Drug
ST*
ST
ST
ST
ST
ST
SMT
SMT
Initia
4.0
4.0
4.0
4.0
4.0
4.0
4.0
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ment with a standard dosage of the drug. That this expectation is
borne out is shown in Fig. 3, in which daily determinations of the
concentration of to-
tal sulfathiazole in SULFATHLZOLE I SULFAPYRSN
the blood in 79 pa- MO ILOLCVEL a
tients under treat- , 6 1t sPnAL 6
ment are recorded. !
The series includes 94 4
only those cases in
which an initial dose
of 4.0 gm. of sulfa- e *
thiazole, followed OI-i* lso 42
by 1.0 gm. q. 4 h., FIG. 2. Comparison of diffusion of sulfathiazole and
was administered. sulfapyridine into spinal fluid. Dosage in grams; blood Cases with renal and spinal fluid levels in mgm. per cent. Open cirdes =
disease or congestive total sulfathiazole; solid circles free sulfathiazole.
II 0 0~~~~~~~~~~~~~~~~~~~~~
Io
-
0 0
0
3 0 o
0
2 D O
C0 48 11222 0 La 7
- . Z
_>5
HOUJRS DAY OF THERAPY
FIG. 3. Variations in blood concentration of total sulfathiazole in patients
under continued treatment. Median is shown by large circles. Solid circles on
6th to 8th days are determinations 24 hrs. after the last dose of sulfathiazole.
heart failure were excluded and are commented on separately below.
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samples ofblood collected four hours afterthe initial dose of 4.0 gm.
and just prior to the first 1.0 gm. dose of the maintenance treat-
ment. All other determinations, except those recorded in solid dots,
were made on samples ofblood collected at approximately 8:00 A.M.,
four hours after the regular 4:00 A. M. dose of 1.0 gm. and just
before the 8:00 A. M. dose. The solid dots on the 6th, 7th, and 8th
days record blood levels in a few patients made on the day follow-
ingdiscontinuance of therapy. The day on which therapy was begun
was considered the first day of treatment, irrespective of the time
when sulfathiazole was started, the second day oftreatment was con-
sidered as beginning at 7:00 A. M. on the following day, and so on.
The data recorded in.Fig. 3 show awidevariation in blood levels
during the early hours of treatment. While there is still consider-
able variation by the third day and later, a much greater tendency
of the values to group about the median is apparent. The slight
trend toward a lower median as time progresses is, perhaps, related
to increased renal excretion with clinical improvement and the estab-
lishment of convalescence. The range of blood concentrations with
sulfathiazole therapy appears to be quite similar to that with sulfa-
pyridine, the median to be somewhat lower than that for total
sulfapyridine.
Acetylation of sulfathiazole
: One of the major problems associated with the use of sulfa-
pyridine as a chemotherapeutic agent is the highly variable and
unpredictable degree of conjugation to the acetyl derivative over a
wide range from 15 to 75 per cent or more which commonly occurs
in patients under treatment with this drug.3 ',25 This difficulty, on
the other hand, is not encountered to more than a minor extent
with sulfanilamide.19 24
The degree of acetylation of sulfathiazole has been studied from
day to day in a large series of patients. As representative of the
group the data on the same patients included in Fig. 3 are shown in
Fig. 4, which records the daily per cent of total sulfathiazole in the
blood that was acetylated. It will be seen that the degree of acety-
lation, with few exceptions, falls within the relatively narrow range
between 0 and 30 per cent, the median being approximately 12 per
cent. The conjugation of sulfathiazole in man, therefore, is appar-
ently comparable in degree to that of sulfanilamide and is not exces-
sive, as it frequently is with sulfapyridine.
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Reference to Tables 2 and 3 will show that the percentage of
acetylated sulfathiazole found in the urine is also relatively low,
rarely exceeding 25 per cent and that only after 18 hours or more
following the last dose of sulfathiazole administered. Acetyl sulfa-
thiazole, however, is highly insoluble'0 and examination of urinary
sediments has shown that it may be present in crystalline form in the
urine (Figs. 5 and 6). Whilewe have not as yet encountered anuria
due to obstruction ofurinary flow by sulfathiazole concretions, Gross,
Cooper, and Scott' have found that crystallization of the drug
occurred in the distal collecting tubules of white rats receiving sulfa-
thiazole. Knoll and Cooper"2 have recorded a case of urolithiasis
medicamentosa with gross hematuria due to this drug, and Pepper
SsU
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-45
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C.30 48 '~ *60e2 *4I
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discovered at autopsy. nm 0 . .
J 1 4 8 12 6 0 24 2a34 5m
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FIG. 4. Daily observations on the percentage of acetylated sulfathiazole
in patients under continued treatment. Same cases as those of Fig. 3.
and Horack22 have reported a case in which concretions obstructing
the renal tubules and in the renal pelves and in the bladder were
discovered at autopsy.
Analysis of the data in Table 4 indicates.that acetylated sulfa-
thiazole does not diffuse so rapidly into pleural and ascitic fluids as
does free sulfathiazole, only free drug being present in the 4-hour
specimens even when the acetyl compound was present in the blood.
It has already been pointed out that little or no acetylated sulfathia-
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zole was found in spinal fluids even as long as 24 to 43 hours after
the initial dose ofthe drug was administered.
The effect of heart failure and impaired renal function on the con,
centration of free and acetylated sulfathiazole in the blood
In the series of patients which we have treated with sulfathiazole
up to the present time, there have been two with congestive heart
failure, two with seriously impaired renal function. All were started
on an initial dose of 4.0 gm. followed by 1.0 gm. q. 4 h. Observa-
tions on these cases are presented in Table 6. In Case C.B., with
fairly severe congestive failure and diminished output of urine, the
TABLE 6
EFFECT OF HEART FAILURE AND IMPAIRED RENAL FUNCTION ON BLOOD CONCENTRATION;
AND ACErYLATION OF SULFATHIAZOLE
Pn. D a y o f t r e a t m e n t
Case Age Type Sulfathiazole 1 2 3 4 5 6 7 8
C.B. 46 IX Total daily
(Arteriosclerotic dose, gm. 5 6 6 6 3(d)
heart disease, Bloodconc. ST. ... 7.6 9.7 15.9 14.8 6.4 1.5
congestive mgm. %t F. . 5.3 4.3 8.4 7.8 2.7 0.5
failure) Acetylated, % ... 30.0 56.0 47.0 47.0 58.0 67.0
(Blood NPN,
mgm. %) ... 54 ... ... 70 64 ...
J.L. 71 III Total daily
(Arteriosclerotic dose, gm. 8 6 4.5 3 3 3 0.5(d)-
heart disease, Bloodconc. IT. 5.1* 11.3 11.3 5.2 4.6 3.6 4.2 TR,
congestive mgm. %9 t F. 4.8 10.0 10.0 4.6 4.4 3.6 3.6 TR.
failure) Acetylated, % 6.0 12.0 12.0 12.0 4.0 0 13.0
(Blood NPN,
mgm. %) 31 ... 35 ... ... ... 33 ...
F.M. 60 III Total daily
(Barbiturate dose, gm. 6 6 5 0.5(d) -
poisoning, im- Bloodconc. 5 T. 5.3* 10.0 19.0 20.5 12.9 5.4
paired renal mgm. %l F. 4.5 7.0 10.5 12.4 6.1 3.1
function) Acetylated, % 15.0 30.0 45.0 40.0 53.0 43.0
(Blood NPN,
mgm. %) ... 90 ... 110 ... ... ... 67
F.Ma. 45 - Total daily
(Undetermined in- dose, gm. 8 6 2(d)
fection, impaired Bloodconc. $ T. 5.1* 17.3f 24.5 18.7 11.4 7.2 2.0
renal function) mgm. % t F. 4.8 15.6 20.0 13.7 8.3 4.9 1.4
Acetylated, % 6.0 10.0 18.0 27.0 27.0 32.0 ... 30.0
(Blood NPN,
mgm. %) 105 ... 105 94 100 101
*= 4 hrs. after initial dose of 4.0 gm. sulfathiazole. t 10.00 P. M. (d) = sulfathiazole
discontinued. T. = total sulfathiazole. F. = free sulfathiazole. TR. = trace.BEHAVIOR OF SULFATHIAZOLE IN MAN
blood level of total sulfathiazole rose progressively to 15.9 mgm.
per cent on the fourth day and the degree of acetylation was exces-
sively high, possibly due to continued recirculation of the drug
through the liver; in Case J. L. with less severe failure the concen-
tration of sulfathiazole in the blood increased rapidly but was quickly
controlled by promptly cutting the dosage in half. In both cases
with impaired renal function and azotemia the blood levels rose
rapidly to excessively high levels and diminished quite slowly when
treatment was discontinued. In Case F. M. acetylation also was
excessively high. These cases serve to illustrate the caution required
in the treatment of patients who have cardiac or renal failure.
Discussion
These observations on the pharmacological properties of sulfa-
thiazole indicate that absorption and excretion of the drug are suffi-
ciently rapid to require spacing of doses at four-hour intervals in
order to maintain adequate and relatively constant blood concentra-
tions throughout the period of therapy. They also show that an
initial dose of 4.0 gm. followed by 1.0 gm. every four hours serves
to establish promptly and to maintain an appropriate blood level
in the great majority of patients. Under special circumstances, how-
ever, particularly in patients with congestive heart failure or with
significantly impaired renal function, these doses may be excessive
and may quickly result in undesirably high concentrations of sulfa-
thiazole in the blood. The dosage in all such patients should be
regulated by careful attention to blood levels.
The ready diffusion of sulfathiazole into pleural fluid suggests
that this compound should often be chemotherapeutically effective
in the early stages of infected pleural effusions associated with the
coccal pneumonias, at least before they have developed into frankly
purulent empyemas. On the other hand, the relatively poor dif-
fusion of sulfathiazole into spinal fluid suggests the possibility that
it may not be a satisfactory agent for the treatment of meningitis.
As already pointed out, however, observations on non-inflammatory
spinal fluids may not be applicable and the question needs further
study in actual cases of acute meningitis.
In harmony with the observations of others, it has been found
that sulfathiazole is not acetylated to an excessive degree except in
very rare instances. In this respect sulfathiazole possesses a con-
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siderable advantage over sulfapyridine, not only because the amount
of inactive acetyl derivative in patients under treatment will be rela-
tively small but also because the necessity for determining both the
total and free concentrations of sulfathiazole in the blood is elimi-
nated, the latter being adequate for routine purposes.
While the low degree of acetylation of sulfathiazole is com-
parable to that of sulfanilamide, it must be borne in mind, however,
that acetylsulfathiazole, unlike acetylsulfanilamide, is highly insol-
uble and consequently may readily precipitate out in crystalline form
in the urine with resultant interference with urinary flow. As stated
above, this has been shown to occur in experimental animals, though
less frequently than in the case with sulfapyridine.' For this reason
patients under treatment with sulfathiazole should have fluids forced
sufliciently to prevent the urine from becoming concentrated. Par-
ticular caution should be observed in patients who are dehydrated
or who have congestive heart failure or renal disease.
Sumnmary
Observations on the absorption, excretion, diffusion, and acetyla-
tion of sulfathiazole in man have been presented. They show (1)
that sulfathiazole is readily absorbed and excreted; (2) that there
is considerable individual variation in capacity to absorb the drug,
though not enough to interfere with the use of a standard dosage in
the great majority of patients; (3) that sulfathiazole readily diffuses
into pleural and ascitic fluids but very poorly into non-inflammatory
spinal fluids; and (4) that acetylation of sulfathiazole is not exces-
sive, only rarely exceeding 30 per cent in the blood and urine, but
because of its high insolubility precipitation of crystals of acetyl
sulfathiazole may, nevertheless, occur in the urine. Finally, some
of the clinical implications of these observations on the pharmaco-
logical properties of sulfathiazole have been briefly discussed.
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FiG. 5. Acetylated sulfathiazole crystals in urine. (X 700). Case A. P. with
temporary microscopic hematuria. Analysis of unfiltered urine with crystalline sedi-
ment in suspension: sulfathiazole, free 55 mgm. per cent, total 90 mgm. per cent,
acetylated 39 per cent; of filtered urine free of crystals: sulfathiazole, free 50
mgm. per cent, total 70 mgm. per cent, acetylated 29 per cent.
FiG. 6. Acetylated sulfathiazole crystals in urine. (X 350). Case L. 1). with
temporary oliguria and albuminuria. Analysis of the dried crystalline sediment
showed that 86 per cent of the total sulfathiazole was acetylated.